The 331 patients had an average age of 44.5 ± 13.9 years; 59.2% were women. The mean dose of lithium was 898 ± 294 mg/day; 22% received doses lower than recommended, and patients had received lithium for 38.0 ± 39.5 months (range: 12-159 months). Lithium levels in blood had been measured only in 13.5% of patients; 71.3% of them had received adjuvant therapy for bipolar disorder with other drugs, especially clozapine (16.6%) and valproic acid (16.6%). The main comorbidities were hypothyroidism (18.1%) and hypertension (12.7%); 390 potentially toxic drug interactions were found, and adverse reactions were reported in 1.2% of patients. A statistically significant association was found between a lower risk of combination therapy and receiving treatment in the cities of Bogotá (OR=0.4, p=0.025), Cartagena (OR=0.3, p=0.015) and Ibagué (OR=0.3, p=0.025).
To be continued
331人の患者は平均年齢44.5±13.9歳で、59.2％が女性だった。リチウムの平均投与量は1日898±294mgで、22%が推奨投与量より低く受けて、患者は38.0±39.5カ月（範囲：12-159カ月）間リチウムを受けていた。血液中のリチウムレベルは患者の13.5%のみ測定され、そのうち71.3%は双極性障害の治療薬、特にクロザピン(16.6%)とパルプロ酸(16.6%)の他に補助薬を受けていた。主な共存症は甲状腺機能低下症(18.1%)と高血圧症(12.7%)で、390の潜在的な有毒薬物相互作用が見つかった。さらに副作用は1.2%の患者で報告された。ボゴタ(OR=0.4, p=0.025)、カルタヘナ(OR=0.3, p=0.015)、イバゲ(OR=0.3, p=0.025)の町ではリスクがより低い併用療法と治療を受けている間で、統計的に明らかな関連性がわかった。